Acumen Pharmaceuticals (ABOS)


Market Price (11/16/2026): $0.204 | Market Cap: $14.8 MilSector: Health Care | Industry: Biotechnology

Acumen Pharmaceuticals (ABOS)


Market Price (11/16/2026): $0.204
Market Cap: $14.8 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -344%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Alzheimer's Disease Therapeutics, Biopharmaceutical R&D, Show more.

Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -163%

Penny stock
Mkt Price is 0.2

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -105 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -690%

High stock price volatility
Vol 12M is 123%

Key risks
ABOS key risks include [1] its singular dependence on the clinical trial success of its sole product candidate, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -344%
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Alzheimer's Disease Therapeutics, Biopharmaceutical R&D, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -163%
3 Penny stock
Mkt Price is 0.2
4 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -105 Mil
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -690%
7 High stock price volatility
Vol 12M is 123%
8 Key risks
ABOS key risks include [1] its singular dependence on the clinical trial success of its sole product candidate, Show more.

ABOS in ETFs

Weight = ABOS's share of each fund

VTI0.00%
IWM0.00%
VTWO0.00%
IWN0.00%
DFAS0.00%
DFAC0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 12: down 5.2% in one day (S&P 500 down 0.4%)
The stock declined without company news. The broader market also moved down.

Down 91.2% from its Oct 28 high to Oct 30 (S&P 500 down 2.1%)
The stock declined significantly without company news during a broader market downturn. Market headlines on October 30 reported a tech market correction and punishment of tech stocks.

Oct 26: up 14.6% on its earnings report (S&P 500 up 0.7%)
The stock gained after Acumen Pharmaceuticals reported Third Quarter 2026 financial results and business highlights. The company announced it expects topline results for its Phase 2 study in November 2026.

Show more
Prices as of 11/13/2026

Nov 12: down 5.2% in one day (S&P 500 down 0.4%)
The stock declined without company news. The broader market also moved down.

Down 91.2% from its Oct 28 high to Oct 30 (S&P 500 down 2.1%)
The stock declined significantly without company news during a broader market downturn. Market headlines on October 30 reported a tech market correction and punishment of tech stocks.

Oct 26: up 14.6% on its earnings report (S&P 500 up 0.7%)
The stock gained after Acumen Pharmaceuticals reported Third Quarter 2026 financial results and business highlights. The company announced it expects topline results for its Phase 2 study in November 2026.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -90.0% change in ABOS stock from 7/31/2026 to 11/15/2026 was primarily driven by a -12.6% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611152026Change
Stock Price ($)2.150.21-90.0%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)6372-12.6%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/15/2026
ReturnCorrelation
ABOS-90.0% 
Market (SPY)1.2%27.9%
Sector (XLV)16.6%7.3%

Fundamental Drivers

The -91.0% change in ABOS stock from 4/30/2026 to 11/15/2026 was primarily driven by a -16.2% change in the company's Shares Outstanding (Mil).
(LTM values as of)430202611152026Change
Stock Price ($)2.390.21-91.0%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)6172-16.2%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/15/2026
ReturnCorrelation
ABOS-91.0% 
Market (SPY)5.5%26.0%
Sector (XLV)30.4%8.6%

Fundamental Drivers

The -90.3% change in ABOS stock from 10/31/2025 to 11/15/2026 was primarily driven by a -16.2% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202511152026Change
Stock Price ($)2.210.21-90.3%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)6172-16.2%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/15/2026
ReturnCorrelation
ABOS-90.3% 
Market (SPY)11.8%28.3%
Sector (XLV)33.1%10.7%

Fundamental Drivers

The -88.6% change in ABOS stock from 10/31/2023 to 11/15/2026 was primarily driven by a -43.3% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202311152026Change
Stock Price ($)1.870.21-88.6%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)4172-43.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/15/2026
ReturnCorrelation
ABOS-88.6% 
Market (SPY)87.0%27.4%
Sector (XLV)59.4%17.3%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
ABOS Return-66%-20%-29%-55%23%-90%-99%
Peers Return54%-24%6%-26%13%4%7%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
ABOS Win Rate17%42%42%25%50%64% 
Peers Win Rate45%47%42%38%48%51% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
ABOS Max Drawdown--54%-81%-63%-53%-94% 
Peers Max Drawdown-39%-49%-47%-59%-55%-46% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: LLY, BIIB, ALEC, CGTX, AVXL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

EventABOSS&P 500
2025 US Tariff Shock
  % Loss-35.7%-18.8%
  % Gain to Breakeven55.4%23.1%
  Time to Breakeven85 days79 days
2023 SVB Regional Banking Crisis
  % Loss-34.8%-6.7%
  % Gain to Breakeven53.5%7.1%
  Time to Breakeven21 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-54.2%-24.5%
  % Gain to Breakeven118.5%32.4%
  Time to Breakeven121 days427 days

Compare to LLY, BIIB, ALEC, CGTX, AVXL

In The Past

Acumen Pharmaceuticals's stock fell -35.7% during the 2025 US Tariff Shock. Such a loss loss requires a 55.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventABOSS&P 500
2025 US Tariff Shock
  % Loss-35.7%-18.8%
  % Gain to Breakeven55.4%23.1%
  Time to Breakeven85 days79 days
2023 SVB Regional Banking Crisis
  % Loss-34.8%-6.7%
  % Gain to Breakeven53.5%7.1%
  Time to Breakeven21 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-54.2%-24.5%
  % Gain to Breakeven118.5%32.4%
  Time to Breakeven121 days427 days

Compare to LLY, BIIB, ALEC, CGTX, AVXL

In The Past

Acumen Pharmaceuticals's stock fell -35.7% during the 2025 US Tariff Shock. Such a loss loss requires a 55.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals (ABOS) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies for Alzheimer's disease. Headquartered in Charlottesville, Virginia, the company focuses its research and development efforts on addressing this significant unmet medical need within the neurodegenerative disease space.

The company's primary product candidate is ACU193, a humanized monoclonal antibody. ACU193 represents a targeted immunotherapy drug designed to combat Alzheimer's by specifically targeting soluble amyloid-beta oligomers, which are believed to play a critical role in the disease's progression. This drug is currently in Phase I clinical trials, a crucial early stage of human testing to evaluate its safety and preliminary efficacy.

Acumen Pharmaceuticals aims to serve the global market of patients suffering from Alzheimer's disease, offering a potential new treatment avenue in a field with significant therapeutic challenges and a high unmet medical need.

AI Analysis | Feedback

An early-stage Biogen, but specialized in developing a novel Alzheimer's treatment.

Like a startup Eli Lilly, entirely focused on a breakthrough Alzheimer's drug candidate.

AI Analysis | Feedback

  • ACU193: A humanized monoclonal antibody drug candidate in Phase I clinical trials, designed to target soluble amyloid-beta oligomers for the treatment of Alzheimer's disease.

AI Analysis | Feedback

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company. At this stage, the company is focused on the research, development, and clinical trials of its drug candidate ACU193. It does not currently have any approved products on the market for sale, and therefore, does not have major customers in the traditional sense of selling products or services.

AI Analysis | Feedback

null

AI Analysis | Feedback

Daniel O'Connell, Chief Executive Officer

Mr. O'Connell has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc. since December 2014. He has over 20 years of venture creation, venture investment, and start-up operations experience, with a focus on neuroscience companies. Under his leadership, Acumen transitioned from a privately-held, pre-clinical biotech company to a publicly-traded clinical-stage company. Mr. O'Connell previously co-founded and served as President and Chief Executive Officer of Functional Neuromodulation Ltd., a clinical-stage company developing deep brain stimulation therapies for Alzheimer's disease. He is also a founding member and former managing partner of NeuroVentures Capital, LLC, a firm involved in investing in emerging neuroscience companies. His involvement with Acumen began as a seed investor.

Matthew Zuga, Chief Financial Officer & Chief Business Officer

Mr. Zuga has served as Chief Financial Officer and Chief Business Officer of Acumen Pharmaceuticals since May 2021. From June 2020 through June 2021, he also served as Chief Financial Officer and Chief Operating Officer and a board member of HighCape Capital Acquisition Corp. Since October 2013, Mr. Zuga has been a partner of HighCape Capital, LLC. He was an advisor to Acumen from July 2019 through April 2021. Mr. Zuga currently serves on the board of directors of Aziyo Biologics, Inc. His background includes working with HighCape Capital, LLC and HighCape Capital Acquisition Corp., indicating a pattern of involvement with investment firms that back companies, which often include private equity firms.

Jim Doherty, PhD, President & Chief Development Officer

Dr. Doherty was appointed President and Chief Development Officer effective February 1, 2024. He brings decades of neuroscience-focused research and clinical development expertise, spanning from discovery through drug approval. Prior to joining Acumen, Dr. Doherty served as Chief Development Officer at Sage Therapeutics, where his team achieved U.S. Food and Drug Administration approvals for two treatments for postpartum depression, Zulresso and Zurzuvae. Before his tenure at Sage, he was the Director and Head of the Neuroscience Department for the Central Nervous System and Pain Innovative Medicines Unit of AstraZeneca Pharmaceuticals.

Eric Siemers, MD, Chief Medical Officer

Dr. Siemers joined Acumen as Chief Medical Officer in 2018 and has over 25 years of experience overseeing clinical trials for neurodegenerative diseases. From 1998, he was with Eli Lilly and Company, where he was responsible for several Alzheimer's compounds' clinical trials, including five Phase III studies. Before Lilly, Dr. Siemers founded and headed the Indiana University Movement Disorder Clinic. He was a founding member of the Alzheimer's Association Research Roundtable and served on the steering committee for the Alzheimer's Disease Neuroimaging Initiative.

Russell Barton, MS, Chief Operating Officer

Mr. Barton serves as the Chief Operating Officer of Acumen Pharmaceuticals.

AI Analysis | Feedback

```html

1. Clinical Development and Regulatory Approval Risk: Acumen Pharmaceuticals' primary asset, ACU193, is in Phase I clinical trials for Alzheimer's disease. The success of the company is almost entirely dependent on the successful advancement of this single product candidate through extensive and costly clinical trials (Phase I, II, and III) and subsequent regulatory approval. A significant percentage of drug candidates fail at various stages of clinical development due to a lack of efficacy, safety concerns, or other issues. Failure to demonstrate the drug's safety and efficacy, or to obtain regulatory approval from agencies such as the FDA, would severely jeopardize the company's business prospects.

2. Competition and Market Acceptance Risk: The field of Alzheimer's disease research and treatment is highly competitive, with many large pharmaceutical companies and biotechnology firms actively developing therapies. Even if ACU193 successfully completes clinical trials and receives regulatory approval, it will face intense competition from other approved treatments (if any are available at that time) and other investigational drugs in various stages of development. There is no guarantee that ACU193, if approved, will achieve significant market acceptance or commercial success against existing or future competitors.

3. Dependence on a Single Product Candidate: Acumen Pharmaceuticals' business is currently focused exclusively on the development of ACU193. The company's future is therefore entirely reliant on the successful development, approval, and commercialization of this one drug candidate. The failure of ACU193 at any stage of development or commercialization would have a profound negative impact on the company, as there are no other pipeline assets mentioned to diversify its risk.

```

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable market for Acumen Pharmaceuticals' main product, ACU193, which targets Alzheimer's disease by selectively focusing on toxic soluble amyloid-beta oligomers, is part of the broader and rapidly expanding global Alzheimer's disease therapeutics market.

The global Alzheimer's therapeutics market was estimated to be approximately USD 6.49 billion in 2025 and is projected to reach around USD 33.62 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 20.06% from 2025 to 2034. Another estimate places the global market at USD 5.36 billion in 2024, anticipated to grow to US$ 31.04 billion by 2034, with a CAGR of 19.2% from 2025 to 2034. A separate report estimated the global market size at USD 13.10 billion in 2025, expected to grow to USD 23.19 billion by 2032, at a CAGR of 8.5% from 2025 to 2032.

North America is a significant region within this market, having dominated the global Alzheimer's therapeutics market with a share of 46.10% in 2024. In 2022, North America held over 40.79% of the market share. The U.S. Alzheimer's drugs market alone was valued at USD 1.62 billion in 2022 and is projected to grow. As of October 2023, the U.S. market for Alzheimer's disease treatment was approximately $2,623 million, with an expectation to grow to $9,553 million by 2028.

ACU193 is a humanized monoclonal antibody, and the anti-amyloid monoclonal antibodies segment is projected to grow at a 12.80% CAGR from 2025 to 2034. Disease-modifying therapies (DMTs), which include drugs targeting amyloid-beta, are expected to dominate the global Alzheimer's market, contributing 69.2% of the market by 2033.

AI Analysis | Feedback

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company primarily focused on developing its lead drug candidate, ACU193 (sabirnetug), for the treatment of Alzheimer's disease. As the company does not yet have commercialized products, its future revenue growth over the next 2-3 years will primarily be driven by key developmental milestones and strategic partnerships related to its pipeline.

Here are 3-5 expected drivers of future revenue growth for Acumen Pharmaceuticals:

  1. Positive Topline Results from the ALTITUDE-AD Phase 2 Study: A critical driver for Acumen Pharmaceuticals is the successful readout of topline results from its Phase 2 ALTITUDE-AD study for sabirnetug (ACU193), which is anticipated in late 2026. Positive data demonstrating efficacy and safety could significantly de-risk the program, attract potential partners for further development and commercialization, or pave the way for a pivotal Phase 3 study.
  2. Achievement of Milestone Payments from Strategic Partnerships: Acumen Pharmaceuticals has engaged in strategic collaborations, such as with JCR Pharmaceuticals for the development of an Enhanced Brain Delivery (EBD™) therapy for Alzheimer's disease. Such partnerships include the potential for significant milestone payments (e.g., up to $555 million from the JCR collaboration), which would directly contribute to the company's revenue.
  3. Advancement of ACU193 into Later-Stage Clinical Development: Following successful Phase 2 results, the progression of ACU193 into a pivotal Phase 3 clinical trial would be a major step towards potential market approval. This advancement would significantly enhance the drug's value and attractiveness for larger pharmaceutical partners, potentially leading to lucrative licensing agreements or co-development deals that include upfront payments and future royalties.
  4. Development and Progression of Additional Formulations or Next-Generation Candidates: Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE® drug delivery technology and developing new AβO-targeting antibodies. Progress in these areas could broaden the market potential for ACU193 or lead to new product candidates, attracting further investment and potential partnership opportunities that could generate revenue through milestone payments or future licensing.

AI Analysis | Feedback

Capital Allocation Decisions for Acumen Pharmaceuticals (ABOS)

Share Issuance

  • Acumen Pharmaceuticals completed its Initial Public Offering (IPO) on July 1, 2021, with shares initially priced at $20.10 each.
  • The number of common shares outstanding significantly increased from 0 in March 2021 to approximately 60.57 million by August 2025.
  • The company recorded proceeds from the issuance of common stock, net of issuance costs, amounting to $7.94 million for the three months ending March 31, 2024.

Inbound Investments

  • Acumen Pharmaceuticals has a substantial institutional investor base, with 146 institutions collectively holding over 40 million shares.
  • In November 2023, the company entered into a Loan and Security Agreement, securing a $50.0 million term loan facility, and initially borrowed $30.0 million.
  • The company's business model relies on funding from investors, partnerships, and licensing agreements to generate revenue and support its R&D efforts.

Outbound Investments

  • On July 15, 2025, Acumen Pharmaceuticals entered a strategic collaboration, option, and license agreement with JCR Pharmaceuticals, which includes an upfront payment and potential future option payments if Acumen exercises its rights to develop certain products.
  • The company has a collaboration and license agreement with Halozyme, Inc. to develop a subcutaneous formulation of its drug candidate, Sabirnetug (ACU193).

Capital Expenditures

  • Acumen Pharmaceuticals reported minimal traditional capital expenditures, with $0.000 million USD in the most recent quarter and -$88,000 in the last 12 months, indicating a focus away from significant physical asset purchases.
  • The primary allocation of capital is towards research and development, with expenses rising to $62.4 million for the six months ended June 30, 2025, driven by costs associated with manufacturing, materials, and clinical trials for its lead drug candidate, ACU193.
  • The company continues to invest in personnel and infrastructure to support its extensive research and development activities for advancing its clinical programs.

Peer Outperformance in Biotechnology

ABOS has trailed 80% of its 364 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Biotechnology constituents that ABOS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
7%
of 451 industry peers · -87.6% return
3Y
20%
of 397 industry peers · -90.4% return
5Y
20%
of 364 industry peers · -98.2% return
No Biotechnology peer with a comparable growth profile has beaten ABOS by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is ABOS's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 10.3%56.1%108.0% CAH 517% · MCK 409% · COR 206%
Health Care Services 20 30.9%20.9%12.5% RDNT 145% · HIMS 141% · DGX 95%
Managed Health Care 8 72.3%-2.6%2.7% OSCR 155% · HQY 54% · HUM 8%
Health Care Facilities 26 18.0%25.0%-6.7% THC 257% · NHC 227% · EHC 196%
Health Care Equipment 50 7.8%11.1%-15.2% GKOS 401% · UFPT 346% · TMDX 255%
Pharmaceuticals 60 -15.0%7.7%-39.5% LQDA 1081% · KNSA 639% · XERS 572%
Health Care Supplies 11 26.2%6.1%-39.8% LNTH 241% · HAE 112% · MMSI 27%
Life Sciences Tools & Services 109 -15.3%-17.9%-74.4% AXGN 378% · MEDP 199% · NTRA 175%
Biotechnology ← 365 -26.3%-32.0%-81.4% ELVN 1259% · TRVI 1141% · DNTH 1129%
Health Care Technology 22 -20.8%-57.2%-82.3% VEEV -4% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Acumen Pharmaceuticals Earnings Notes12/16/2025
Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

ABOSLLYBIIBALECCGTXAVXLMedian
NameAcumen P.Eli LillyBiogen Alector Cognitio.Anavex L. 
Mkt Price0.201,454.00255.062.500.680.931.72
Mkt Cap0.01,296.837.70.30.10.10.2
Rev LTM086,46210,2971730087
Op Inc LTM-10544,3151,80735-17-189
FCF LTM-8811,6891,644-150-15-29-22
FCF 3Y Avg-935,2831,892-190-23-32-28
CFO LTM-8830,6452,247-150-15-29-22
CFO 3Y Avg-9317,5802,276-189-23-32-28

Growth & Margins

ABOSLLYBIIBALECCGTXAVXLMedian
NameAcumen P.Eli LillyBiogen Alector Cognitio.Anavex L. 
Rev Chg LTM-45.5%2.3%151.2%--45.5%
Rev Chg 3Y Avg-39.4%1.1%42.5%--39.4%
Rev Chg Q-38.6%10.6%4,895.9%--38.6%
QoQ Delta Rev Chg LTM-8.5%2.7%1,151.3%--8.5%
Op Inc Chg LTM24.2%67.9%-29.2%128.3%39.7%68.0%53.8%
Op Inc Chg 3Y Avg-29.3%68.3%0.9%48.5%1.6%23.0%12.3%
Op Mgn LTM-51.3%17.6%20.2%--20.2%
Op Mgn 3Y Avg-43.7%22.2%-153.4%--22.2%
QoQ Delta Op Mgn LTM-1.5%-1.7%932.6%--1.5%
CFO/Rev LTM-35.4%21.8%-86.4%--21.8%
CFO/Rev 3Y Avg-25.7%22.8%-243.8%--22.8%
FCF/Rev LTM-13.5%16.0%-86.5%--13.5%
FCF/Rev 3Y Avg-6.3%18.9%-244.7%--6.3%

Valuation

ABOSLLYBIIBALECCGTXAVXLMedian
NameAcumen P.Eli LillyBiogen Alector Cognitio.Anavex L. 
Mkt Cap0.01,296.837.70.30.10.10.2
P/S-15.03.71.6--3.7
P/Op Inc-0.129.320.98.0-3.8-4.83.9
P/EBIT-0.129.350.38.0-4.0-6.73.9
P/E-0.147.0108.56.8-4.0-6.63.3
P/CFO-0.242.316.8-1.9-4.2-2.9-1.0
Total Yield-684.5%2.6%0.9%14.6%-24.7%-15.1%-7.1%
Dividend Yield0.0%0.5%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-73.1%0.6%7.4%-62.2%-60.0%-8.9%-34.4%
D/E1.80.00.20.10.00.00.1
Net D/E-3.60.00.2-0.4-0.5-1.4-0.4

Returns

ABOSLLYBIIBALECCGTXAVXLMedian
NameAcumen P.Eli LillyBiogen Alector Cognitio.Anavex L. 
1M Rtn-87.9%15.8%9.6%35.9%-6.8%-28.7%1.4%
3M Rtn-92.4%23.4%21.6%27.6%-32.7%-71.0%-5.6%
6M Rtn-91.1%45.1%32.2%15.7%-40.4%-67.9%-12.3%
12M Rtn-88.2%42.7%52.2%101.6%-56.1%-74.4%-6.7%
3Y Rtn-90.9%151.9%11.2%-36.5%-32.0%-84.5%-34.3%
1M Excs Rtn-86.2%17.9%10.0%32.5%-5.6%-35.3%2.2%
3M Excs Rtn-90.8%24.7%23.6%23.5%-31.7%-69.3%-4.1%
6M Excs Rtn-93.8%42.2%29.3%12.9%-43.2%-70.8%-15.1%
12M Excs Rtn-100.2%32.6%46.7%75.5%-71.7%-97.7%-19.5%
3Y Excs Rtn-160.4%65.6%-64.2%-125.8%-114.2%-158.2%-120.0%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil2020
Research and development of sabirnetug for the treatment of patients with Alzheimer’s disease (AD)1
Total1


Net Income by Segment
$ Mil202520242023
Research and development of sabirnetug for the treatment of patients with Alzheimer’s disease (AD)-121-102-52
Total-121-102-52


Assets by Segment
$ Mil202320222021
Research and development of sabirnetug for the treatment of patients with Alzheimer’s disease (AD)310197230
Total310197230


Price Behavior

Price Behavior
Market Price$0.21 
Market Cap ($ Bil)0.0 
First Trading Date07/01/2021 
Distance from 52W High-93.6% 
   50 Days200 Days
DMA Price$1.85$2.40
DMA Trenddowndown
Distance from DMA-88.4%-91.1%
 3M1YR
Volatility201.6%122.9%
Downside Capture1352.56488.31
Upside Capture250.41186.18
Correlation (S&P 500)28.1%27.7%
ABOS Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta16.529.577.323.752.961.76
Up Beta9.16-2.33-1.092.081.981.32
Down Beta29.8425.6122.817.725.052.01
Up Capture472%282%376%167%269%459%
Bmk +ve Days12182862130427
Stock +ve Days10203361121346
Down Capture1406%779%615%319%190%113%
Bmk -ve Days10253664121325
Stock -ve Days11222960123376

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ABOS
ABOS-89.1%122.9%-0.36-
Sector ETF (XLV)25.8%16.8%1.1810.6%
Equity (SPY)11.6%13.7%0.5427.5%
Gold (GLD)-7.9%28.9%-0.2926.3%
Commodities (DBC)33.8%21.3%1.26-4.2%
Real Estate (VNQ)10.7%14.2%0.479.8%
Bitcoin (BTCUSD)-33.0%43.7%-0.7914.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ABOS
ABOS-57.4%105.7%-0.17-
Sector ETF (XLV)9.1%15.4%0.3919.2%
Equity (SPY)11.5%17.3%0.4924.9%
Gold (GLD)15.9%19.2%0.6613.9%
Commodities (DBC)7.8%19.6%0.282.5%
Real Estate (VNQ)1.3%18.9%-0.0418.3%
Bitcoin (BTCUSD)2.2%51.6%0.2317.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with ABOS
ABOS-36.7%103.7%-0.20-
Sector ETF (XLV)13.0%16.8%0.6418.8%
Equity (SPY)15.5%18.0%0.7324.6%
Gold (GLD)11.1%16.6%0.5413.4%
Commodities (DBC)7.6%18.1%0.331.9%
Real Estate (VNQ)6.3%20.7%0.2617.8%
Bitcoin (BTCUSD)58.4%66.2%0.9816.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity4.6 Mil
Short Interest: % Change Since 1015202647.4%
Average Daily Volume6.9 Mil
Days-to-Cover Short Interest1
Basic Shares Quantity72.3 Mil
Short % of Basic Shares6.3%

Earnings Returns History

Updated 11/5/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/26/202614.6%-89.4% 
8/12/20261.6%10.9%15.8%
5/12/2026-3.5%-15.2%-12.8%
3/26/2026-3.0%-3.0%-2.3%
11/12/2025-1.0%-15.7%8.6%
8/12/2025-11.3%0.7%-4.9%
5/13/20250.0%1.9%8.6%
3/27/20256.0%-6.9%-6.9%
...
SUMMARY STATS   
# Positive13118
# Negative81012
Median Positive6.0%10.5%8.9%
Median Negative-7.3%-13.7%-13.5%
Max Positive18.1%27.8%47.9%
Max Negative-16.9%-89.4%-49.5%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/26/202614.6%-89.4% 
8/12/20261.6%10.9%15.8%
5/12/2026-3.5%-15.2%-12.8%
3/26/2026-3.0%-3.0%-2.3%
11/12/2025-1.0%-15.7%8.6%
8/12/2025-11.3%0.7%-4.9%
5/13/20250.0%1.9%8.6%
3/27/20256.0%-6.9%-6.9%
11/12/2024-16.9%-30.4%-32.3%
8/13/20248.2%10.5%-3.5%
5/14/20249.8%14.3%-19.6%
3/26/2024-11.8%-10.8%-25.2%
11/13/20236.8%20.0%47.9%
8/8/20230.0%3.1%-15.3%
5/9/202318.1%27.8%3.5%
11/14/20225.0%3.4%-6.2%
8/15/20224.4%-7.4%9.2%
5/16/202213.0%6.8%11.1%
3/28/2022-6.0%-12.2%-14.2%
11/15/2021-8.5%-23.9%-49.5%
8/16/20210.8%15.0%0.3%
SUMMARY STATS   
# Positive13118
# Negative81012
Median Positive6.0%10.5%8.9%
Median Negative-7.3%-13.7%-13.5%
Max Positive18.1%27.8%47.9%
Max Negative-16.9%-89.4%-49.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202610/26/202610-Q
06/30/202608/12/202610-Q
03/31/202605/12/202610-Q
12/31/202503/26/202610-K
09/30/202511/12/202510-Q
06/30/202508/12/202510-Q
03/31/202505/13/202510-Q
12/31/202403/27/202510-K
09/30/202411/12/202410-Q
06/30/202408/13/202410-Q
03/31/202405/14/202410-Q
12/31/202303/26/202410-K
09/30/202311/13/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/27/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202610/26/202610-Q
06/30/202608/12/202610-Q
03/31/202605/12/202610-Q
12/31/202503/26/202610-K
09/30/202511/12/202510-Q
06/30/202508/12/202510-Q
03/31/202505/13/202510-Q
12/31/202403/27/202510-K
09/30/202411/12/202410-Q
06/30/202408/13/202410-Q
03/31/202405/14/202410-Q
12/31/202303/26/202410-K
09/30/202311/13/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/27/202310-K
09/30/202211/14/202210-Q
06/30/202208/15/202210-Q
03/31/202205/16/202210-Q
12/31/202103/28/202210-K
09/30/202111/15/202110-Q
06/30/202108/16/202110-Q
03/31/202107/02/2021424B4

Insider Activity

Updated 6/10/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Fountain, Nathan B DirectSell61020262.236,40014,273107,379Form
2Meisner, Derek MChief Legal Officer & Corp SecDirectSell31020263.262,0906,813567,237Form
3Meisner, Derek MChief Legal Officer & Corp SecDirectSell30320263.019,40628,311523,720Form
4Meisner, Derek MChief Legal Officer & Corp SecDirectSell12820263.002,6718,017522,275Form
5Meisner, Derek MChief Legal Officer & Corp SecDirectSell12820263.0015,08545,263522,084Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Fountain, Nathan B DirectSell61020262.236,40014,273107,379Form
2Meisner, Derek MChief Legal Officer & Corp SecDirectSell31020263.262,0906,813567,237Form
3Meisner, Derek MChief Legal Officer & Corp SecDirectSell30320263.019,40628,311523,720Form
4Meisner, Derek MChief Legal Officer & Corp SecDirectSell12820263.002,6718,017522,275Form
5Meisner, Derek MChief Legal Officer & Corp SecDirectSell12820263.0015,08545,263522,084Form
6Meisner, Derek MChief Legal Officer & Corp SecDirectSell12320261.905,63310,718331,068Form
7Meisner, Derek MChief Legal Officer & Corp SecDirectSell12320261.841,0541,939330,523Form
8Siemers, EricChief Medical OfficerDirectSell12320261.828951,629464,775Form
9Zuga, MattCFO & Chief Business OfficerDirectSell12320261.861,6873,138567,159Form
10Oconnell, Daniel JosephChief Executive OfficerDirectSell12320261.882,6895,0661,660,146Form
11Barton, RussellChief Operating OfficerDirectSell12320261.84462850377,369Form
12Meisner, Derek MChief Legal Officer & Corp SecDirectSell12320261.812,2474,063326,734Form
13Siemers, EricChief Medical OfficerDirectSell12320261.802,3314,204462,176Form
14Zuga, MattCFO & Chief Business OfficerDirectSell12320261.812,4734,469554,107Form
15Oconnell, Daniel JosephChief Executive OfficerDirectSell12320261.819,34616,9271,601,036Form
16Barton, RussellChief Operating OfficerDirectSell12320261.812,3154,181371,231Form
17Doherty, James JPresident and CDODirectSell10920261.826,46711,76998,329Form
18Doherty, James JPresident and CDODirectSell10920261.991,7003,379120,268Form
19Schacterle, AmyChief Regulatory OfficerDirectSell10920261.981,0972,17615,281Form

Investor Activity (13F)

Updated Nov 16, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sands Capital Alternatives, LLC$8.8 Mil2.1%21ADD +8.9%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sands Capital Alternatives, LLC$8.8 Mil2.1%21ADD +8.9%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sands Capital Alternatives, LLC$8.8 Mil2.1%21ADD +8.9%13F
Core Cache Last Updated: 11/15/2026